Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06345482

A Study of MHB039A for Advanced Solid Tumor

A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety

Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd

Interventions MHB039A

Updated 4 times since 2024 Last updated: Nov 17, 2025 Started: Apr 16, 2024 Primary completion: Apr 1, 2028 Completion: Jun 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06345482, this PHASE1/PHASE2 trial focuses on Advanced Solid Tumor and remains ongoing. Sponsored by Minghui Pharmaceutical (Hangzhou) Ltd, it has been updated 4 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Active Not Recruiting
Sep 2024 — Dec 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Minghui Pharmaceutical (Hangzhou) Ltd

Data source: Minghui Pharmaceutical (Hangzhou) Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China